Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York City, NY 10065, USA.
Cancer J. 2010 Jan-Feb;16(1):39-47. doi: 10.1097/PPO.0b013e3181cf0204.
Germline mutations in the BRCA1 and BRCA2 genes are characterized by deficient repair of DNA double-strand breaks by homologous recombination. Defective DNA double-strand break repair has been not only implicated as a key contributor to tumorigenesis in mutation carriers but also represents a potential target for therapy. The transcriptional similarities between BRCA1-deficient tumors and sporadic tumors of the basal-like subtype have led to the investigation of homologous recombination repair-directed therapy in triple-negative tumors, which demonstrates overlap with the basal-like subtype. We broaden the scope of this topic by addressing a "repair-defective" rather than "BRCA1-like" phenotype. We discuss structural and functional aspects of key repair proteins including BRCA1, BRCA2, BRCA1 interacting protein C-terminal helicase 1, and partner and localizer of BRCA2 and describe the phenotypic consequences of their loss at the cellular, tissue, and organism level. We review potential mechanisms of repair pathway dysfunction in sporadic tumors and address how the identification of such defects may guide the application of repair-directed therapies.
BRCA1 和 BRCA2 基因中的种系突变的特征是同源重组修复 DNA 双链断裂的缺陷。DNA 双链断裂修复缺陷不仅被认为是突变携带者肿瘤发生的关键因素,而且代表了治疗的潜在靶点。BRCA1 缺陷型肿瘤与基底样亚型的散发性肿瘤之间的转录相似性导致了对三阴性肿瘤的同源重组修复靶向治疗的研究,这与基底样亚型重叠。我们通过解决“修复缺陷”而不是“BRCA1 样”表型来扩展这个话题。我们讨论了关键修复蛋白的结构和功能方面,包括 BRCA1、BRCA2、BRCA1 相互作用蛋白 C 端解旋酶 1 以及 BRCA2 的伙伴和定位器,并描述了它们在细胞、组织和机体水平丧失的表型后果。我们回顾了散发性肿瘤中修复途径功能障碍的潜在机制,并探讨了如何确定这些缺陷可能指导修复靶向治疗的应用。